FDA’s Struggle with Tavneos: Experts Push for Drug Reassessment
The debate surrounding the approval of Tavneos, a treatment for a rare disease, has intensified as experts express their skepticism regarding its safety and efficacy. Joshua Skydel, a clinical fellow in rheumatology at Yale New Haven Hospital, emphasizes that under current regulations, there should be reconsideration of Tavneos’ market status. He critiqued the drug’s pivotal trial, suggesting that the evidence supporting its approval is insufficient and calling for published studies to undergo thorough peer review. “I’d at least like to see them go through peer review before hanging my hat on them,” he stated.
Meanwhile, Kristin Høeg shares concerns that new clinical evidence collected since the drug’s approval may not bolster its position. Høeg noted that the real-world data, much of which was already accessible during a withdrawal request made in April, may fall short of the FDA‘s standards for approval. She reminded stakeholders that this data was deemed inadequate for maintaining marketing authorization in both the EU and UK.
Another point raised by Skydel highlights the FDA’s initial request for Amgen, the maker of Tavneos, to conduct additional post-marketing studies—studies that have reportedly been delayed. He remarked, “This episode really, for me, highlighted the way that drugs are allowed to reach the market with open questions,” stressing that effective collaboration between the FDA and the pharmaceutical industry is crucial to address these issues comprehensively.
In a significant statement from the FDA, the agency articulated that the ramifications of this debate extend beyond mere regulatory compliance, underlining the importance of protecting public health and the drug approval system’s integrity. The FDA cautioned that without consequences, there may be an increased risk of deceptive actions by pharmaceutical companies.
Walter Kraft, who supported the recommendation for Tavneos based on existing information, has expressed concerns regarding the implications of compromised trust within the clinical trial system. “The clinical trial system is built on a level of trust,” Kraft said. “When that trust is put into question for a narrow parochial gain, it puts the whole system at risk for other subsequent actors in the space.”
This article was originally published on Undark. Read the original article.
Editor’s Take
The FDA’s reevaluation of Tavneos represents a critical juncture in drug approval processes, emphasizing the necessity for stringent standards. As the debate heightens, pharmaceutical companies must prioritize transparency and evidence-based practice. This situation serves as a reminder of the delicate balance in drug development, where public health and trust are paramount.
Source: arstechnica.com
